Fronteggiare l’inaffidabilità della letteratura da studi clinici

The document discussed the unreliability of literature from randomized controlled trials due to reporting bias and the fragility of editorial quality control, which could be exploited for marketing by the pharmaceutical industry. It suggested that regulatory documents might be more reliable, but they also had limitations for long-term use in research synthesis and decision-making. The author proposed that public health decisions and reimbursement for interventions should be based on independent trials and studies, following the model of the Mario Negri Institute of Pharmacological Research, rather than attempting to reform the existing systems of research, industry, government, regulation, and publishing.